JAZZ: Jazz Pharma Company Value to Net Income

Jazz Pharmaceuticals relies on exclusive patents for the treatment of epilepsy and sleep disorders. High margins are ensured by strict cold chain control during the delivery of oncology drugs. This price-to-earnings chart confirms financial stability, and the 74.60 value captures this metric. Stringent FDA safety requirements for narcolepsy medications create a powerful barrier to entry for low-cost generics.

Jazz Pharma - JAZZ P/E Multiple (period 07/04/2022 - 11/14/2026)

Analytical breakdowns for Jazz Pharmaceuticals

- price and consensus price forecast:

Stock Price Jazz Pharma|JAZZ - Consensus Target

- market capitalization information:

Market Value Jazz Pharma|JAZZ - Total Company Value

- balance sheet net asset value indicators:

Equity per Share Jazz Pharmaceuticals|JAZZ - Book Capitalization|Market-to-Book Ratio jazzpharma.com|JAZZ - Cumulative Company Assets

- company liabilities and liquidity data:

- financial results and valuation multiples details:

JAZZ - Net Profit|Projected Net Profit Jazz Pharmaceuticals|JAZZ - Price to Earnings Ratio|Projected Price to Earnings Ratio Jazz Pharmaceuticals Corp|JAZZ - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Ratio Jazz Pharmaceuticals PLC|JAZZ - Operating profit EBITDA|Net earnings per share (EPS TTM) Jazz Pharmaceuticals|JAZZ - Net earnings per share for the last 12 months|Year-over-year net earnings per share trend for the last twelve months jazzpharma.com|JAZZ - Net earnings per share growth this year|Net earnings per share change forecast for next year Jazz Pharmaceuticals

- company sales and revenue statistics:

JAZZ - Company Sales|Company Future Revenue Jazz Pharmaceuticals PLC|JAZZ - Price-to-Revenue Ratio|Future Price to Revenue Jazz Pharmaceuticals PLC

Comprehensive company analysis:JAZZ (Jazz Pharmaceuticals PLC)

Core merchandise of Jazz Pharmaceuticals Corp

The P/E ratio compares a stock's market value to its net income, allowing for an assessment of the investment payback period and the impact of fiscal preferences on the business's real income. By analyzing the P/E multiple, an investor determines the degree of overpayment for the asset, which is critical for Jazz Pharmaceuticals (JAZZ), whose stability is based on the diversification of its orphan drug portfolio in neurology and oncology.

Analysis of competing companies